The Global Burden of Cervical Cancer: A Systematic Review of Social Implications, Ethical Considerations, and Scientific Challenges

Hyunsuh Choi

January 29th 2025

Curing with Care Cervical Cancer Research Competition

Table of Contents

Introduction

Cervical cancer, a type of cancer that starts in the cells of the cervix, remains a significant global health challenge as it accounts for over 600,000 new cases and approximately 340,000 deaths annually with the majority occurring in low- and middle-income countries (World Health Organization, 2021). Despite advancements in human papillomavirus (HPV) vaccination and improvements in screening methods, disparities in accessibility and awareness continue to hinder global efforts to eradicate the disease (Arbyn et al., 2019). These disparities highlight a complex interplay of scientific, social, and ethical challenges in the fight against cervical cancer.

Efforts to combat cervical cancer through widespread HPV vaccination programs have shown promise, particularly in regions with robust healthcare systems. Vaccination coverage in some high-income countries exceeds 70%, resulting in significant reductions in HPV prevalence and related cervical cancer cases (Brisson et al., 2020). However, in many underprivileged regions, barriers such as vaccine affordability, lack of infrastructure, and cultural resistance persist, limiting the efficacy of preventive measures. Additionally, advancements in screening, such as liquid-based cytology and HPV DNA testing, have improved early detection, but these technologies are often inaccessible to resource-poor communities (Bray et al., 2018).

The social implications of cervical cancer eradication efforts include addressing gender inequality, as women in underserved areas frequently lack access to adequate healthcare. Ethical considerations emerge in ensuring equitable distribution of prevention and treatment resources, especially in light of the significant costs associated with advanced diagnostic tools and vaccines. From a scientific perspective, ongoing challenges include the development of affordable

point-of-care diagnostics and vaccines effective against a broader spectrum of HPV strains.

This review will discuss the current obstacles to cervical cancer eradication, focusing on societal and ethical challenges, while exploring the latest research directions aimed at improving early detection, prevention, and treatment. By summarizing existing findings and critically analyzing the barriers and opportunities, this paper will contribute to a deeper understanding of the path toward cervical cancer elimination.

Methodology



Figure 1 ; Methodology of Bibliometric Analysis Flowchart

Societal Implications



Figure 2 ; Frequently Occuring Keywords Graph in Social Implications



Figure 3 ; Trending Keywords per Year in Social Implications

Impact of Demographic Changes and Access to Care

According to Figure 2 and Figure 3 from the data provided, there is a clear association between the terms "disparities," "access," and "burden" in the context of cervical cancer. These keywords suggest a significant societal burden caused by cervical cancer, with disparities in access to care being a key contributing factor. As the burden term appears frequently, it indicates the growing concern surrounding the disproportionate impact cervical cancer has on certain populations, especially women in low-resource settings.

The analysis of Figure 2 and Figure 3 reveals that the burden of cervical cancer is particularly pronounced in lower-income and developing countries, where access to effective prevention and treatment is limited. This aligns with Figure 3, which highlights that regions with fewer healthcare resources are more heavily impacted by cervical cancer. This suggests that demographic factors, such as age, gender, and socio-economic status, play a crucial role in the likelihood of both contracting and surviving cervical cancer. These findings reflect global patterns observed in the disease burden, where women in their reproductive and middle years (typically aged 30-50) are the most affected by cervical cancer (Riano et al., 2023).

Socioeconomic Disparities and Socioeconomic Determinants

Figure 2 also highlights terms like "inequality" and "socioeconomic," indicating the profound influence of socioeconomic factors on cervical cancer outcomes. Women in lower socioeconomic strata are particularly vulnerable to cervical cancer, primarily due to barriers in accessing healthcare services like HPV vaccination, screening, and treatment. As shown in the data, access to healthcare is a significant issue, and those with lower income often face additional barriers

such as the high cost of healthcare services and lack of education on prevention methods.

Studies confirm these disparities, noting that women from lower-income backgrounds are more likely to be diagnosed at later stages of cervical cancer, leading to higher mortality rates (Chavez et al., 2020). Furthermore, rural populations often experience even greater barriers to care, with fewer healthcare facilities, limited healthcare providers, and limited access to preventive services (Sullivan & Glover, 2022). The frequency of terms related to disparities and burden in the data points to these persistent issues, underlining the urgent need for policies addressing these inequities.

Geographic Disparities and Regional Differences

Figure 3 also indicates geographic disparities in the impact of cervical cancer. It suggests that countries or regions with limited healthcare resources, particularly those in Africa, Asia, and parts of Latin America, face a disproportionate burden from cervical cancer. The frequent appearance of "global" and "healthcare access" points to how geographic location influences the disease's burden. In many lower-income countries, the lack of widespread access to the HPV vaccine, screening programs, and treatment options means that cervical cancer is often diagnosed at later, less treatable stages (Murillo et al., 2021).

This geographic variation is further supported by global health reports indicating that cervical cancer remains a leading cause of cancer-related deaths in low- and middle-income countries (WHO, 2021). A study by Lee et al. (2021) found that geographic location significantly impacts cervical cancer incidence and outcomes, with countries in sub-Saharan Africa and parts of Southeast Asia reporting the highest mortality rates due to a combination of low screening rates,

lack of prevention programs, and limited treatment access.

Age and Social Determinants of Health

Age remains a critical factor in cervical cancer incidence and outcomes. Figure 3 analysis indicates that cervical cancer incidence increases with age, particularly after the age of 30. This demographic information is crucial for targeted screening and prevention programs. However, women in younger age groups, especially in underprivileged social environments, may also face barriers to early diagnosis and treatment. These barriers, compounded by social determinants such as education and cultural beliefs, contribute to the inequitable burden of cervical cancer (Tan et al., 2021).

The presence of terms like **"**awareness**"** in the data further indicates that a lack of knowledge about cervical cancer prevention contributes to delayed diagnoses, especially among underserved populations. Public health efforts to increase awareness and provide education about HPV and cervical cancer prevention can help mitigate these social barriers, but they must be adapted to the cultural and social contexts of different populations (Chavez et al., 2020).

Ethical Considerations



Figure 4 ; Frequently Occuring Keyword Graph in Ethical Consideration

Figure 5 ; Co-occurrence Keywords Map in Ethical Consideration

Gender Bias in HPV Vaccination and Prevention

Figure 5 from the provided data above reveals a significant association between "women" and "health," particularly focusing on "prevention" and "HPV." This indicates that the majority of

HPV vaccination and cervical cancer prevention efforts are primarily directed toward women. While this focus is necessary, given that cervical cancer directly affects women, it raises ethical concerns about the exclusion of men from vaccination programs. HPV also leads to other cancers in men, such as anal and oropharyngeal cancers, which are often overlooked in public health policies. (Dykens et al,. 2023) highlights the importance of including boys in vaccination programs to reduce the global burden of HPV-related diseases, arguing that a gender-neutral vaccination strategy would benefit both men and women equally. This exclusion of men from vaccination initiatives perpetuates an ethical issue regarding gender equity in healthcare. (Hirth 2018)

Equitable Access to Screening and Vaccination

Figure 4 and Figure 5 also underscore concerns regarding unequal access to HPV vaccination and cervical cancer screening. While women are the primary target of these programs, the data suggest that equitable access to these services is still lacking, particularly in low- and middle-income countries. (Riano et al., 2024) note that women in underserved areas often face significant barriers to preventive care, including limited access to vaccination and screening services. This disparity raises ethical questions regarding fairness and justice in healthcare. The principle of justice, which emphasizes the equal distribution of healthcare resources, calls for policies that address these disparities and ensure that all populations, regardless of gender or socioeconomic status, have equal access to preventive services. (Gossa et al.,2020) argue that

global health policies must target underserved populations to reduce the global burden of cervical cancer and ensure equitable access to preventive care for both men and women.

Cultural and Religious Barriers

Figure 4 and Figure 5 suggest that cultural and religious beliefs may impact the uptake of HPV vaccination, particularly in regions where sexual health is a sensitive topic. Khan (et al., 2023) highlights that conservative cultural and religious values can create resistance to vaccination, as HPV is associated with sexual health. This creates an ethical dilemma, as public health officials must balance the need to protect public health with respecting cultural and religious values. Torres-Roman (2024) emphasizes that health interventions must be culturally sensitive to gain acceptance while promoting the importance of vaccination for preventing HPV-related diseases. Ethical policy making requires careful navigation of these cultural barriers, ensuring that health interventions are both respectful of local traditions and effective in promoting public health.

Stereotypes and Health Education

Figure 5 further reveals a gendered focus in HPV health education, where women are primarily educated about cervical cancer and HPV prevention. This reinforces the stereotype that HPV is a "women's disease," while men's risks are often ignored. Chao (2019) argues that this selective focus on women in health education can prevent men from seeking vaccination and screening, thereby perpetuating gender-based health disparities. To address these ethical concerns, health education campaigns must include both men and women, providing accurate information about HPV-related risks for both genders. Public health messages should emphasize that HPV affects everyone, regardless of gender, and promote vaccination as a preventive measure for both men and women.

Scientific Challenges



Figure 6 ; Trending Keywords per Year in Scientific Challenges



Figure 7 ; Co-occurrence Keywords Map in Scientific Challenges

Emerging Use of Artificial Intelligence and Machine Learning

Figure 6 and figure 7 highlight the increased prominence of terms like "artificial intelligence," "early detection," and "screening" in the context of cervical cancer. This suggests an increasing interest in incorporating AI and machine learning (ML) into cervical cancer diagnosis, with the

goal of improving early detection. AI's potential in medical diagnostics is particularly evident in imaging techniques, which can significantly reduce diagnostic errors and enhance screening efficiency. Recent studies show that AI models are being trained to analyze cervical smear images and identify precancerous lesions with high accuracy (Hou et al., 2022). Wu et al. (2024) demonstrated that AI-driven diagnostic tools could detect high-risk HPV strains and early-stage cervical lesions at a comparable level to experienced pathologists, offering significant potential for improving cervical cancer detection.

However, the widespread adoption of AI in cervical cancer diagnosis faces several challenges, particularly around ensuring the consistency and quality of the data used for training these models. AI algorithms often require large, high-quality datasets to perform optimally, but such datasets are not always readily available, particularly in low-resource settings where cervical cancer incidence is highest. Cheung et al. (2021) highlight that inconsistencies in imaging quality and equipment between different healthcare settings can result in diagnostic variability, which hinders the broader application of AI in clinical practice.

Technological Limitations and Failures

While AI has shown promise in the early detection of cervical cancer, technological limitations persist. The data emphasize that diagnostic tools must be robust and capable of functioning across a variety of clinical environments. A significant barrier is the variability in healthcare

infrastructure, particularly in low-income countries. AI models trained on high-quality images may not perform as well with lower-quality images commonly found in resource-poor settings (Esteva et al., 2017). Additionally, while AI can assist in detecting early-stage cancer, it still

relies on human oversight and interpretation, and it cannot fully replace the role of clinicians in making final diagnostic decisions (Cheung et al., 2022).

Furthermore, the complexity of cervical cancer and the variability in individual patient cases pose challenges for AI to achieve consistent diagnostic performance across all populations. According to Wu et al. (2024), AI systems need more diverse training datasets to ensure they work effectively across different demographics, including various age groups, ethnicities, and geographical regions.

Challenges in Funding and Healthcare Disparities

Figure 7 also indicates a significant focus on "funding" and "screening," suggesting that financial limitations and disparities in healthcare access continue to present major challenges in the fight against cervical cancer. AI and machine learning technologies, despite their potential, require substantial financial investment for development and implementation. In countries with limited resources, securing funding for such advanced technologies can be difficult, and this often results in a lack of access to cutting-edge diagnostic tools (Biddell et al., 2021). As noted by the WHO (2021), while cervical cancer incidence has decreased in high-income countries due to effective screening programs, the burden remains disproportionately high in low- and middle-income countries due to inadequate screening infrastructure and lack of access to preventive care.

Addressing this disparity requires targeted investments in both the development of AI technologies and their deployment in underserved areas. Funding must be allocated not only for

the research and development of new tools but also for the necessary infrastructure to implement these tools in low-resource settings (Gossa et al., 2020).

Ethical and Technological Challenges Moving Forward

Despite significant advancements in cervical cancer detection technologies, the implementation of these solutions continues to face challenges. The balance between leveraging AI for early detection and ensuring accessibility across all healthcare systems, particularly in low-income regions, remains a key issue. Further research and innovation are required to create AI models that are adaptable to a wide range of healthcare environments and that provide accurate, actionable results in diverse clinical settings (Hou et al., 2022).

Future Directions

Advances in HPV Vaccination

One of the most promising future directions in cervical cancer prevention lies in the advancement of HPV vaccination. Currently, HPV vaccines are highly effective against the most prevalent strains of HPV responsible for cervical cancer (HPV types 16 and 18). However, there are more than 200 HPV types, and only a subset is targeted by existing vaccines. As seen in the data trends, there is a growing emphasis on broadening the scope of HPV vaccination to include protection against a wider range of oncogenic HPV strains (Williamson, 2023). Innovations in vaccine development, such as multivalent vaccine**s** that cover more HPV strains, could further reduce the global burden of cervical cancer. The future of vaccination also includes exploring universal vaccines that can target both existing and emerging HPV strains, making vaccination more effective in preventing cervical and other HPV-related cancers (Harper et al., 2011). Additionally, new vaccine formulations with improved cost-effectiveness could make HPV vaccination more accessible in low- and middle-income countries where cervical cancer remains

a significant public health issue (Brisson et al., 2020).

Molecular Testing and Screening Techniques

Advancements in molecular testing and screening technologies will likely revolutionize the early detection of cervical cancer. While current methods, such as Pap smears and HPV testing, have significantly improved early diagnosis, molecular testing offers the potential for more precise and personalized detection. For example, genomic-based screening could identify women at high risk of developing cervical cancer before the onset of detectable lesions (Kundrod et al., 2020). Moreover, the integration of liquid biopsy techniques could enable non-invasive monitoring of

HPV infections and early cancer markers, making regular screening more convenient and less costly. These developments could enable early intervention, reducing the need for invasive procedures and improving patient outcomes.

The growing interest in AI and machine learning for analyzing molecular and cytological data also represents a significant technological advancement in cervical cancer screening. AI-driven diagnostics can improve the sensitivity and specificity of screenings by identifying subtle biomarkers that may be missed by human pathologists (Hou et al., 2022). Despite the potential, challenges in standardization and widespread adoption remain. Ensuring that these advanced screening methods are accessible across diverse healthcare settings, including low-resource environments, is crucial for their global impact (Esteva et al., 2021).

Novel Therapeutic Options: Immunotherapy and Targeted Treatments

Beyond prevention and early detection, the development of novel therapeutic options offers new

hope for treating cervical cancer, particularly in advanced stages. One promising area of research is immunotherapy, which leverages the body's immune system to target and destroy cancer cells. Recent studies have demonstrated that immunotherapies, such as checkpoint inhibitors, show potential in treating HPV-related cancers, including cervical cancer (Silva et al., 2023). The ability to combine immunotherapy with existing treatments, such as chemotherapy and radiation, could improve patient prognosis, especially for those with recurrent or metastatic disease.

Targeted therapies that focus on the specific molecular pathways involved in cervical cancer pathogenesis are also an area of intense research. Drugs that target the E6/E7 oncoproteins of HPV are being developed, as these proteins are responsible for disrupting the normal function of host cell machinery, leading to tumorigenesis. Early-phase clinical trials indicate promising

results, and this therapeutic approach may offer a new avenue for treating HPV-positive cervical cancers (Peralta-Zaragoza et al., 2012).

Improving Accessibility in Low-Resource Settings

While these advances in vaccination, screening, and treatment are groundbreaking, they will be ineffective unless they are made accessible to the populations who need them the most. As highlighted in the data, geographic disparities in healthcare access continue to exacerbate the global burden of cervical cancer, especially in low- and middle-income countries. A critical challenge moving forward is improving accessibility to these advanced medical technologies in underserved regions.

Efforts to improve access should focus on both affordability and infrastructure development. For instance, reducing the cost of vaccines, diagnostic tests, and treatment options through global

partnerships and subsidized pricing models can make these interventions accessible to lower-income populations (Biddell et al., 2021). Additionally, mobile health technology (mHealth) can be leveraged to deliver educational campaigns and screening services to remote areas, where access to healthcare facilities is limited (Zhang et al., 2022). Furthermore, telemedicine and telepathology could enhance the capabilities of healthcare providers in underserved regions, allowing for remote consultations and diagnoses, which would improve access to timely care (Chao et al., 2019).

Conclusion

Cervical cancer remains a significant global health challenge, especially in low- and middle-income countries, despite advancements in prevention and early detection methods. The efforts to combat the disease, particularly through HPV vaccination and improved screening techniques, have made a measurable impact, yet disparities in access to care and cultural barriers persist. Socioeconomic inequalities and geographic disparities exacerbate the burden, particularly in underserved regions. Ethical challenges, such as ensuring equitable distribution of healthcare resources, also continue to hinder progress.

As research moves forward, innovation in HPV vaccination, molecular testing, and immunotherapy is crucial to expanding the effectiveness of prevention and treatment. More accessible diagnostic tools, affordable vaccines, and targeted therapies must be developed and adapted for low-resource settings to ensure that all populations benefit from advancements in cervical cancer care. The future of cervical cancer eradication will rely heavily on overcoming these barriers through technological innovation and a global commitment to reducing inequities in healthcare access.

Addressing these gaps will require a concerted effort to ensure that advanced medical technologies are not confined to high-income nations but are instead made available to those most in need. By prioritizing global accessibility, improving healthcare infrastructure, and fostering international collaborations, significant progress can be made toward the elimination of cervical cancer worldwide. With continued innovation and research, the future offers hope for a world where cervical cancer no longer presents a major health threat to the globe.

Work Cited

Arbyn, M., Weiderpass, E., Bruni, L., De Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2019). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *The Lancet Global Health*, *8*(2), e191–e203. https://doi.org/10.1016/s2214-109x(19)30482-6

Bedford, H., Firman, N., Waller, J., Marlow, L., Forster, A., & Dezateux, C. (2021). Which young women are not being vaccinated against HPV? Cross-sectional analysis of a UK national cohort study. *Vaccine*, *39*(40), 5934–5939. https://doi.org/10.1016/j.vaccine.2021.07.094

Biddell, C. B., Spees, L. P., Smith, J. S., Brewer, N. T., Marais, A. C. D., Sanusi, B. O., Hudgens, M. G., Barclay, L., Jackson, S., Kent, E. E., & Wheeler, S. B. (2021). Perceived financial barriers to cervical cancer screening and associated cost burden among Low-Income, Under-Screened women. *Journal of Women S Health*, *30*(9), 1243–1252. https://doi.org/10.1089/jwh.2020.8807

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA a Cancer Journal for Clinicians*, *68*(6), 394–424. https://doi.org/10.3322/caac.21492

Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M., Sy, S., Regan, C., Keane, A., Caruana, M., Nguyen, D. T. N., Smith, M. A.,

Laprise, J., Jit, M., Alary, M., . . . Hutubessy, R. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *The Lancet*, *395*(10224), 575–590. https://doi.org/10.1016/s0140-6736(20)30068-4

Casas, C. P. R., De Cássia Ribeiro De Albuquerque, R., Loureiro, R. B., Gollner, A. M., De Freitas, M. G., Duque, G. P. D. N., & Viscondi, J. Y. K. (2022). Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies. *Clinics*, *77*, 100080. https://doi.org/10.1016/j.clinsp.2022.100080

Chao, Y., Clark, M., Carson, E., Weeks, L., Moulton, K., McFaul, S., McLauchlin, C., Tsoi, B., Majid, U., Kandasamy, S., Arora, N., Vanstone, M., Reid, L., Krahn, T., Kaluzny, K., Farrah, K., & Ford, C. (2019, March 1). *HPV testing for Primary Cervical Cancer screening: A Health Technology assessment*. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK543088/

Cheung, H., & Rubin, D. (2021). Challenges and opportunities for artificial intelligence in oncological imaging. *Clinical Radiology*, *76*(10), 728–736. https://doi.org/10.1016/j.crad.2021.03.009 Ditzian, L. R., David‐West, G., Maza, M., Hartmann, B., Shirazian, T., & Cremer, M. (2011). Cervical cancer screening in Low‐ and Middle‐Income countries. *Mount Sinai Journal of Medicine a Journal of Translational and Personalized Medicine*, *78*(3), 319–326. https://doi.org/10.1002/msj.20263

Drolet, M., Bénard, É., Boily, M., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., Donovan, B., Fairley, C. K., Flagg, E. W., Johnson, A. M., Kahn, J. A., Kavanagh, K., Kjaer, S. K., Kliewer, E. V., Lemieux-Mellouki, P., . . . Brisson, M. (2015). Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, *15*(5), 565–580. https://doi.org/10.1016/s1473-3099(14)71073-4

Dykens, J. A., Peterson, C. E., Holt, H. K., & Harper, D. M. (2023a). Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally. *Frontiers in Public Health*, *11*. https://doi.org/10.3389/fpubh.2023.1067299

Dykens, J. A., Peterson, C. E., Holt, H. K., & Harper, D. M. (2023b). Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally. *Frontiers in Public Health*, *11*. https://doi.org/10.3389/fpubh.2023.1067299

Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature*, *542*(7639), 115–118. https://doi.org/10.1038/nature21056

Franco, E. L., De Sanjosé, S., Broker, T. R., Stanley, M. A., Chevarie-Davis, M., Isidean, S. D., & Schiffman, M. (2012). Human papillomavirus and cancer prevention: Gaps in knowledge and prospects for research, policy, and advocacy. *Vaccine*, *30*, F175–F182. https://doi.org/10.1016/j.vaccine.2012.06.092

Gossa, W., & Fetters, M. D. (2020). How should cervical cancer prevention be improved in LMICs? *The AMA Journal of Ethic*, *22*(2), E126-134. https://doi.org/10.1001/amajethics.2020.126 Harper, D. M., & Vierthaler, S. L. (2011). Next generation Cancer Protection: the bivalent HPV vaccine for females. *ISRN Obstetrics and Gynecology*, *2011*, 1–20. https://doi.org/10.5402/2011/457204 Hirth, J. (2018). Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. *Human Vaccines & Immunotherapeutics*, *15*(1), 146–155. https://doi.org/10.1080/21645515.2018.1512453

Hou, X., Shen, G., Zhou, L., Li, Y., Wang, T., & Ma, X. (2022). Artificial intelligence in cervical cancer screening and diagnosis. *Frontiers in Oncology*, *12*. https://doi.org/10.3389/fonc.2022.851367 Kundrod, K. A., Smith, C. A., Hunt, B., Schwarz, R. A., Schmeler, K., & Richards-Kortum, R. (2019). Advances in technologies for cervical cancer detection in low-resource settings. *Expert Review of Molecular*

Diagnostics, *19*(8), 695–714. https://doi.org/10.1080/14737159.2019.1648213 Milano, G., Guarducci, G., Nante, N., Montomoli, E., & Manini, I. (2023). Human papillomavirus Epidemiology and Prevention: Is there still a gender gap? *Vaccines*, *11*(6), 1060. https://doi.org/10.3390/vaccines11061060

Peralta-Zaragoza, O., Bermudez-Morales, N., Perez-Plasencia, N., Salazar-Leon, N., Gomez-Ceron, N., & Madrid-Marina, N. (2012). Targeted treatments for cervical cancer: a review. *OncoTargets and Therapy*, 315. https://doi.org/10.2147/ott.s25123

Publications detail. (n.d.). https://www.who.int/publications-detail-redirect/9789240014107 Rahangdale, L., Teodoro, N., Chinula, L., & Brewer, N. T. (2023). Eliminating cervical cancer as a global public health problem requires equitable action. *BMJ*, p2978. https://doi.org/10.1136/bmj.p2978

Riano, I., Contreras-Chavez, P., Pabon, C. M., Meza, K., Kiel, L., Bejarano, S., & Florez, N. (2023). An overview of cervical cancer prevention and control in Latin America and the Caribbean countries. *Hematology/Oncology Clinics of North America*, *38*(1), 13–33. https://doi.org/10.1016/j.hoc.2023.05.012

Sankaranarayanan, R., Bhatla, N., Gravitt, P. E., Basu, P., Esmy, P. O., Ashrafunnessa, K., Ariyaratne, Y., Shah, A., & Nene, B. M. (2008). Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. *Vaccine*, *26*, M43–M52. https://doi.org/10.1016/j.vaccine.2008.05.005

Silva, A. J. D., De Moura, I. A., Da Gama, M. a. T. M., Leal, L. R. S., De Pinho, S. S., Espinoza, B. C. F., Santos, D. L. D., Santos, V. E. P., De Sena, M. G. a. M., Da Conceição Viana Invenção, M., De Macêdo, L. S., De França Neto, P. L., & De Freitas, A. C. (2023). Advancing immunotherapies for HPV-Related cancers: Exploring novel vaccine strategies and the influence of tumor microenvironment. *Vaccines*, *11*(8), 1354. https://doi.org/10.3390/vaccines11081354

Spencer, J. C., Brewer, N. T., Coyne-Beasley, T., Trogdon, J. G., Weinberger, M., & Wheeler, S. B. (2021). Reducing Poverty-Related Disparities in Cervical Cancer: The role of HPV vaccination.

Cancer Epidemiology Biomarkers & Prevention, *30*(10), 1895–1903. https://doi.org/10.1158/1055-9965.epi-21-0307

Sukrong, M., Prapaisilp, P., Juntamongkol, T., Siranart, N., Phoolcharoen, N., Assavapokee, N., Sirisabya, N., & Santibenchakul, S. (2024). Knowledge regarding human papillomavirus and cervical cancer prevention among medical students from Chulalongkorn University in Thailand. *BMC Women S Health*, *24*(1). https://doi.org/10.1186/s12905-024-02933-3

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA a Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Torres-Roman, J. S., Ronceros-Cardenas, L., Valcarcel, B., Bazalar-Palacios, J., Ybaseta-Medina, J., Carioli, G., La Vecchia, C., & Alvarez, C. S. (2022). Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030. *BMC Public Health*, *22*(1). https://doi.org/10.1186/s12889-021-12413-0

Williamson, A. (2023). Recent developments in human papillomavirus (HPV) vaccinology. *Viruses*, *15*(7), 1440. https://doi.org/10.3390/v15071440

World Health Organization: WHO. (2024, March 5). *Cervical cancer*. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

Wu, T., Lucas, E., Zhao, F., Basu, P., & Qiao, Y. (2024). Artificial intelligence strengthenes cervical cancer screening – present and future. *Cancer Biology and Medicine*, 1–16. https://doi.org/10.20892/j.issn.2095-3941.2024.0198

Zhang, D., Advani, S., Waller, J., Cupertino, A., Hurtado-De-Mendoza, A., Chicaiza, A., Rohloff, P. J., Akinyemiju, T. F., Gharzouzi, E., Huchko, M. J., Barnoya, J., & Braithwaite, D. (2020). Mobile Technologies and Cervical Cancer Screening in Low- and Middle-Income Countries: A Systematic

review. *JCO Global Oncology*, *6*, 617–627. https://doi.org/10.1200/jgo.19.00201

Zhao, M., Wu, Q., Hao, Y., Hu, J., Gao, Y., Zhou, S., & Han, L. (2021). Global, regional, and national burden of cervical cancer for 195 countries and territories, 2007–2017: findings from the Global Burden of Disease Study 2017. *BMC Women S Health*, *21*(1). https://doi.org/10.1186/s12905-021-01571-3